These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 22149905)
21. Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema. Kim M; Lee P; Kim Y; Yu SY; Kwak HW Ophthalmologica; 2011; 226(3):138-44. PubMed ID: 21822008 [TBL] [Abstract][Full Text] [Related]
22. The efficacy of bevacizumab in diabetic macular oedema in a 12-month follow-up. Jamrozy-Witkowska A; Grabska-Liberek I; Skonieczna K Klin Oczna; 2014; 116(4):237-41. PubMed ID: 25906633 [TBL] [Abstract][Full Text] [Related]
23. Repeated intravitreal bevacizumab (Avastin(®)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation. Schmidinger G; Maar N; Bolz M; Scholda C; Schmidt-Erfurth U Acta Ophthalmol; 2011 Feb; 89(1):76-81. PubMed ID: 21272288 [TBL] [Abstract][Full Text] [Related]
24. Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial. Lam DS; Lai TY; Lee VY; Chan CK; Liu DT; Mohamed S; Li CL Retina; 2009 Mar; 29(3):292-9. PubMed ID: 19287286 [TBL] [Abstract][Full Text] [Related]
25. Phacoemulsification with intravitreal bevacizumab and triamcinolone acetonide injection in diabetic patients with clinically significant macular edema and cataract. Akinci A; Muftuoglu O; Altınsoy A; Ozkılıc E Retina; 2011 Apr; 31(4):755-8. PubMed ID: 21124251 [TBL] [Abstract][Full Text] [Related]
26. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months. Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ Retina; 2010; 30(7):1002-11. PubMed ID: 20616679 [TBL] [Abstract][Full Text] [Related]
27. Dramatic response to intravitreal Bevacizumab in hypertensive retinopathy. Padhy S; Kumar V Indian J Ophthalmol; 2018 Oct; 66(10):1494-1495. PubMed ID: 30249851 [TBL] [Abstract][Full Text] [Related]
28. Intravitreal bevacizumab for myopic choroidal neovascularization: short-term and 1-year results. Spielberg L; Leys A Bull Soc Belge Ophtalmol; 2009; (312):17-27. PubMed ID: 19927486 [TBL] [Abstract][Full Text] [Related]
29. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Avery RL; Pearlman J; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ; Wendel R; Patel A Ophthalmology; 2006 Oct; 113(10):1695.e1-15. PubMed ID: 17011951 [TBL] [Abstract][Full Text] [Related]
30. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA; Retina; 2008; 28(10):1387-94. PubMed ID: 18827735 [TBL] [Abstract][Full Text] [Related]
31. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Chan WM; Lai TY; Liu DT; Lam DS Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414 [TBL] [Abstract][Full Text] [Related]
32. [Bevacizumab and Ranibizumab for macular edema due to retinal vein occlusions]. Niederhauser N; Valmaggia C Klin Monbl Augenheilkd; 2013 Apr; 230(4):405-8. PubMed ID: 23629792 [TBL] [Abstract][Full Text] [Related]